Document:

Document

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
Exhibit 10.2
AMENDMENT NO. 1 TO
AGREEMENT
THIS AMENDMENT NO. 1 TO AGREEMENT (this “Amendment”) is made effective as of the 1st day of January, 2005, between IDEXX Operations, Inc., a Delaware corporation whose principal place of business is at 6100 East Shelby Drive, Memphis, Tennessee 38141, U.S.A. (“IDEXX”) and Ortho-Clinical Diagnostics, Inc., a New York corporation with offices at 100 Indigo Creek Drive, Rochester, New York, U.S.A. (“OCD”).
WHEREAS, OCD and IDEXX entered into a certain Agreement dated as of October 16, 2003 (the “Agreement”) regarding supply by OCD of dry slides for IDEXX veterinary chemistry analyzers; and
WHEREAS, OCD and IDEXX desire to amend the Agreement as set forth in this Amendment.
NOW THEREFORE, the parties hereby agree as follows:
1.     Capitalized terms used in this Amendment, which are not otherwise defined, have the respective meanings ascribed to them in the Agreement.
2.     Section 3.08(b) is amended by deleting the same in its entirety and substituting therefor the following provision:
						
	 	Automation Costs shall exclude the cost of any injection molding tooling associated with the New Slide/Panel Design, for which IDEXX shall be solely responsible. The parties shall mutually agree on the selection of a third party vendor for such tooling. IDEXX shall own such tooling. After installation, IDEXX shall be solely responsible for the costs of maintaining, repairing and replacing any such tooling, and costs of spare tooling, in each case to the extent OCD deems necessary to maintain OCD’s piece part cost of the injection molded components at or below the levels realized with tooling that has suffered no degradation.

3.     Section 18.01 is amended by deleting the same in its entirety and substituting therefor the following provision:
						
	 	Subject to the terms and conditions set forth herein, the term (the “Term”) of the Agreement shall be the period from the Commencement Date until December 31, 2020.

4.     Schedule 3, Schedule 5, Schedule 6 and Schedule 8 to the Agreement are amended by deleting the same in their entirety and substituting therefor the respective Schedule 3, Schedule 5, Schedule 6 and Schedule 8 attached to this Amendment.
5.     The price for Vetrol controls (Catalog No. 8699852) supplied hereunder shall be $[**] and the price for tips (Catalog No. 6801762) supplied hereunder shall be $[**].
6.     The per slide prices for single VETTEST slides that are packaged 12 per box shall be the same as the per slide prices of the corresponding single VETTEST slides that are packaged 25 per box.
7.     Except as modified by this Amendment, all provisions of the Agreement shall continue in full force and effect.
IN WITNESS WHEREOF and intending to be legally bound, the parties hereto have caused this Amendment to be duly executed in duplicate by their respective authorized representatives as of the day and year first written above.

									
	ORTHO-CLINICAL
DIAGNOSTICS, INC.		IDEXX OPERATIONS, INC.
	 	 	 
	By: /s/Tony Zezzo	 	By: /s/Laurel LaBauve
	
		

	Name: Tony Zezzo	 	Name: Laurel LaBauve
	
		

	Title: VP Americas	 	Title: President, IDEXX Operations
	
		

	 	 	 
	 	 	Acknowledged and consented to,
	 	 	solely as guarantor pursuant to
	 	 	Section 30 of the Agreement
	 	 	 
	 	 	IDEXX LABORATORIES, INC.
	 	 	 
	 	 	By: /s/Conan R. Deady
			

	 	 	Name: Conan R. Deady
			

	 	 	Title: Vice President
			

 

Schedule 3 — Panels/Profiles
(Applicable only to VETTEST Analyzer)
The initial PANEL shall be the “Pre-Anesthetic Panel” consisting of four sets of the following six VETTEST slides:
						
		
	BUN	Urea Nitrogen
	ALT	Alanine aminotransferase
	GLU	Glucose
	TP	Total protein
	CREA	Creatinine
	ALKP	Alkaline phosphatase
		

The initial PROFILES shall be the “General Health Profile” and the “Large Animal Profile”, each consisting of two sets of 12 VETTEST slides as follows:
												
	General Health Profile		Large Animal Profile	
	ALB	Albumin	ALB	Albumin
	ALKP	Alkaline phosphatase	ALKP	Alkaline phosphatase
	ALT(SGPT)	Alanine aminotransferase	AST	AST
	AMYL	Amylase	Ca2+
	Calcium
	Ca2+
	Calcium	CK	CK
	CHOL	Cholesterol	GGT	Gamma GT
	CREA	Creatinine	GLU	Glucose
	GLU	Glucose	PHOS	Inorganic phosphate
	PHOS	Inorganic phosphate	LDH	LDH
	TBIL	Total bilirubin	MG	Magnesium
	TP	Total protein	TP	Total Protein
	BUN	Urea Nitrogen	BUN	Urea Nitrogen

Effective as of March 4, 2004, “PROFILES” shall also include the “Equine Health Profile,” consisting of two sets of 12 VETTEST slides as follows:
						
		
	ALB	Albumin
	ALKP	Alkaline phosphatase
	AST	AST
	Ca2+
	Calcium
	CK	CK
	GGT	Gamma GT
	GLU	Glucose
	LDH	LDH
	TP	Total protein
	BUN	Urea Nitrogen
	CREA	Creatinine
	TBIL	Total Bilirubin

 

Effective as of May 25, 2004, “PROFILES” shall also include the “Urine P:C Ratio” (OCD cat #6802061), consisting of six pairs of Urine Protein and Creatinine VETTEST slides.
Effective as of June 1, 2005, “PANELS” shall also include the “[**]” (IDEXX part #98-13952-00, OCD cat #6802213), consisting of four sets of the following [**] VETTEST slides:
						
		
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]

Packaging for the Pre-Anesthetic Panels, the General Health Profiles, the Large Animal Profiles, the Equine Health Profiles, the Urine P:C Ratios and the [**] for the VETTEST Analyzer has been previously agreed upon by the parties, and any changes to the slide composition or packaging of the foregoing PANELS or PROFILES shall be negotiated in good faith and mutually agreed upon by OCD and IDEXX. The slide composition, packaging and initial pricing of any additional PANELS/PROFILES shall be mutually agreed upon by OCD and IDEXX. Unless otherwise agreed by the parties in writing with respect to one or more specific PANELS or PROFILES, all purchases by IDEXX or IDEXX BV of VETTEST slides packaged as PANELS/PROFILES shall be credited against the Annual Purchase Forecasts and Purchase Commitments for such slides under this Agreement and the Europe Agreement.
New Slide/Panel Design for the New Analyzer shall be as developed by IDEXX under Article 3.
 

Schedule 5 - Products
(as of January 1, 2005)
																																				
	Single Slides
(Box of 25)

	Catalog Number

	Single Slides
(Box of 12)
(added Dec 11, 2003)

	Catalog Number

	Albumin	 	 	822 7134	 	 	Albumin	 	 	6801907	 	 
	Alk Phos	 	 	831 5459	 	 	Alk Phos	 	 	6801919	 	 
	ALT	 	 	808 3750	 	 	ALT	 	 	6801916	 	 
	Ammonia	 	 	181 6842	 	 	Ammonia	 	 	6801908	 	 
	Amylase	 	 	820 8191	 	 	Amylase	 	 	6801913	 	 
	AST	 	 	811 3979	 	 	AST	 	 	6801914	 	 
	Calcium	 	 	804 8191	 	 	Calcium	 	 	6801902	 	 
	Cholesterol	 	 	835 4888	 	 	Cholesterol	 	 	6801906	 	 
	CK	 	 	835 8582	 	 	CK	 	 	6801918	 	 
	Creatinine	 	 	818 3477	 	 	Creatinine	 	 	6801911	 	 
	ECO2 (HCO3)	 	 	853 8670	 	 	ECO2 (HCO3)	 	 	6802306	 	 
	Gamma GT	 	 	826 1315	 	 	Gamma GT	 	 	6801920	 	 
	Glucose	 	 	813 0536	 	 	Glucose	 	 	6801900	 	 
	LDH	 	 	835 1082	 	 	LDH	 	 	6801917	 	 
	Lipase	 	 	196 6191	 	 	Lipase	 	 	6801915	 	 
	Magnesium	 	 	108 0266	 	 	Magnesium	 	 	6801912	 	 
	Phosphorus	 	 	807 0856	 	 	Phosphorus	 	 	6801909	 	 
	Total Bilirubin	 	 	838 0396	 	 	Total Bilirubin	 	 	6801910	 	 
	Total Protein	 	 	193 7093	 	 	Total Protein	 	 	6801904	 	 
	Triglycerides	 	 	192 2285	 	 	Triglycerides	 	 	6801905	 	 
	Urea Nitrogen	 	 	150 7326	 	 	Urea Nitrogen	 	 	6801901	 	 
	Uric Acid	 	 	100 0793	 	 	Uric Acid	 	 	6801903	 	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	[**] (added as of July 1, 2005)	 	 	6802307	 	 

																																				
	Profile Slides
(Box of 24)

	 	Profile Slides
(Box of 12)

	 
	General Health Profile	 	 	160 7175	 	 	Urine P;C Ratio (added May 25, 2004)	 	 	6802061	 	 
	Pre-Anesthetic Panel	 	 	801 5109	 	 		 	 		 	 
	Large Animal Profile	 	 	680 0071	 	 		 	 		 	 
	Equine Health Panel (added Mar 4, 2004)	 	 	680 1956	 	 		 	 		 	 
	[**] (added as of June 1, 2005)	 	 	680 2213	 	 		 	 		 	 

 																																				
	Other

	 	 	 
	Vetrols	 	 	869 9852	 	 	 	 	 	 	 	 
	Tips	 	 	6801762	 	 		 	 		 	 

Schedule 6 – Minimum Prices for New Chemistries
Urine Protein (added May 25, 2004 as part of the Urine P:C Ratio):
									
	 	•	Prices for 2005 and thereafter shall be determined based on volume tiers pursuant to Section 7.02(b), subject to a minimum price for this New Chemistry of $[**] per slide.

[**]     (added as of July 1, 2005):
									
	 	•	Prices for 2005 and thereafter shall be determined based on volume tiers pursuant to Section 7.02(b), subject to a minimum price for this New Chemistry of $[**] per slide.

 

Schedule 8 – Eligible New Chemistry Slides
						
		
	[**]	 
	[**]	 
	[**]	 
	[**]	 
	[**]	 
	[**]	 
	[**]	 
	[**]	 
	[**]	 
	[**]	 
	[**]	

[*] and [**] text omitted throughout this exhibit for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.Document

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
Exhibit 10.5
AMENDMENT NO. 4 TO AGREEMENT

AMENDMENT, effective as of December 28, 2011 (this “Amendment”) to the Agreement, dated as of October 16, 2003, between IDEXX Operations, Inc. (“IDEXX”) and Ortho-Clinical Diagnostics, Inc. (“OCD”).

WHEREAS, OCD and IDEXX have entered into that certain Agreement dated as of October 16, 2003, as amended by Amendment No. 1 thereto effective January 1, 2005, by Amendment No. 2 thereto effective October 15, 2006, and by Amendment No. 3 thereto effective January 18, 2008 (as so amended, the “Agreement”), regarding supply by OCD of dry slides for IDEXX veterinary chemistry analyzers;

WHEREAS, the parties wish to resolve a dispute under the Agreement as more fully described herein; and

WHEREAS, IDEXX and OCD wish to amend certain terms of the Agreement and the Europe Agreement to reflect the foregoing resolution;

NOW, THEREFORE, the parties agree as follows:

1. DEFINITIONS

In this Amendment, terms capitalized but not defined herein shall have the meanings set forth in the Agreement. The following expressions shall have the meanings set forth opposite them:

     “Dispute”    The dispute between IDEXX and OCD regarding the number of Existing Special [**] Slides that are counted toward Dry Slide volume.

“Difference”    The dollar amount arrived at by [**].

2. SETTLEMENT

The parties acknowledge and agree that the covenants and agreements set forth herein represent a compromise and resolution of the Dispute. In consideration of entering into this Amendment and the corresponding amendment of the Europe Agreement, each party hereby waives and releases any claims such party has, had or may in the future have against any other party regarding the Dispute.

3. PAYMENTS

3.1IDEXX and IDEXX BV collectively shall pay to OCD, as a one-time payment, $[**] upon the execution of this Amendment and the corresponding amendment of the Europe Agreement.
3.2(a) For calendar years 2011 and 2012, OCD will price the Dry Slides in accordance with Section 7.02 of the Agreement, interpreting such Section 7.02 such that [**].
(b)No later than January 31, 2012, representatives from the respective finance departments of IDEXX and OCD will meet to discuss and come to agreement on the Difference.
(c)No later than the [**], IDEXX and IDEXX BV collectively will pay to OCD [**] of the Difference. The Difference payment shall be appropriately taken into account when calculating the Final Blended Price in accordance with Section 7.02(b) of the Agreement.

			
	

4. AMENDMENTS

The parties hereto agree that the Agreement shall be amended as follows:
4.1A new Section 3.10 is hereby added to read in its entirety as follows:
“3.10    IDEXX will devote chemistry instrument development resources to the development and launch of [**].
IDEXX will use commercially reasonable efforts to achieve commercial launch of such analyzer within the United States by [**].”
4.2Effective January 1, 2013 Section 7.02(a) is hereby replaced in its entirety with the following:
7.02(a) The prices for Dry Slides shall be in accordance with Schedule 5. At a given volume of aggregate slide purchases by IDEXX and IDEXX BV in a given calendar year, the corresponding pricing in Schedule 5 applies to the total aggregate volume of slides purchased in such calendar year by IDEXX and IDEXX BV. Effective January 1, 2013, no [**] will apply. In the event of an automatic extension of the Term pursuant to Section 18.02, pricing for calendar years after 2028 shall be increased yearly by [**]% over the prior year.”
4.3Effective January 1, 2013, all text in Section 7.02(b) preceding the paragraph that begins with the phrase “Notwithstanding the foregoing” is hereby deleted.
4.4Effective January 1, 2013, the paragraph beginning with the phrase “Notwithstanding the foregoing” in Section 7.02(b) of the Agreement is hereby amended to read in its entirety as follows:
“The price per slide for any New Chemistry Slide that is priced on Schedule 6 shall never be lower than the greater of (a) the minimum price as determined in accordance with Section 5.06 and identified on Schedule 6 as amended from time to time and (b) the price that would otherwise apply pursuant to Schedule 5.”
4.5Effective January 1, 2013, in Section 7.02(b), each instance of the words “weighted average price” are hereby changed to “price”.
4.6Effective January 1, 2013, the definition “First Estimated Blended Price” is hereby changed to “First Estimated Price”.
4.7Effective January 1, 2013, the definition “Second Estimated Blended Price” is hereby changed to “Second Estimated Price”.
4.8Effective January 1, 2013, the definition “Final Blended Price” is hereby changed to “Final Price”.
4.9Effective January 1, 2013, Section 7.02(c) is hereby deleted.
4.10Effective January 1, 2013, Section 7.02(d) of the Agreement is hereby amended to read in its entirety as follows:

“(d) With respect to slides ordered for delivery on or after January 1, 2013, if OCD’s aggregate cost of all [**] (as defined below) for the most recently completed calendar year has increased on a per VETTEST slide basis as compared with aggregate cost of all [**] for the calendar year preceding the most recently completed calendar year, by an amount that exceeds the [**]% annual increase incorporated into Schedule 5, then OCD shall be permitted to increase the price of each slide sold to IDEXX by the amount of such excess. “[**]” means [**] that are [**]. No later than January 31 of each calendar year during the Term (beginning in 2013), OCD shall provide to IDEXX a summary of all charges for [**] for the previous calendar year and recurring charges that carry forward. IDEXX shall have the option to pay such charges in quarterly installments during the then-current calendar year or as a lump-sum payment no later than March 31 of each then-current calendar year.”

4.11Effective January 1, 2013, Section 7.02(e) of the Agreement is hereby amended to read in its entirety as follows:

“(e) With respect to slides ordered for delivery on or after January 1, 2013, if IDEXX’s share of Special Event Costs (as defined below) for the most recently completed calendar year has increased on a per VETTEST slide basis as compared with IDEXX’s share of Special Event Costs for the calendar year preceding the most recently completed calendar year, by an amount that exceeds [**] above the [**]% annual increase incorporated into Schedule 5, then OCD shall be permitted to increase the price of each slide sold to IDEXX by the amount of such excess. “Special Event Costs” means the aggregate net amount of (i) [**] with respect to [**] on which [**], (ii) [**] in the [**], and (iii) [**] as a result of [**]. “IDEXX’s share” of any of the foregoing shall mean the [**] that is attributable to the [**]. No later than January 31 of each calendar year during the Term (beginning in 2013), OCD shall provide to IDEXX a summary of all Special Events Costs for the previous calendar year. IDEXX shall have the option to pay such Special Events Costs in quarterly installments during the then-current calendar year or as a lump-sum payment no later than March 31 of each then-current calendar year.”

			
	

4.12Section 9.04(c) of the Agreement is hereby amended to read in its entirety as follows:
“(c) Should IDEXX sell or cause to be sold for use in the field of diagnostic testing of non-human animals any product, other than the New Analyzer (which includes without limitation [**]), whose scope includes four or more of the chemistries identified on Schedule 5, then OCD may, in its sole discretion, terminate the provisions of Section 9.04(a) immediately upon written notice to IDEXX. If OCD delivers such notice of termination of Section 9.04(a) under this Section 9.04(c), then IDEXX may in its discretion terminate the provisions of Section 9.03(a) of this Agreement immediately upon written notice to OCD.”
4.13Section 18.01 of the Agreement is hereby amended by changing the year “2018” to the year “2028”.
4.14A new Section 18.02 is hereby added to read in its entirety as follows:
“18.02    This Agreement may be terminated by either party upon [**] written notice to the other party; provided, however, that no such termination shall be effective prior to December 31, 2028. If neither party provides such written notice, the then-current term of this Agreement shall automatically be extended for an additional three (3) years, and no termination under this Section 18.02 shall be effective prior to the end of such additional term. Within 60 days of either party providing such notice, the senior leaders of each of the parties shall meet to discuss the relationship of the parties.”
4.15Effective January 1, 2013, Schedule 5 is hereby replaced in its entirety by Schedule 5 attached hereto.
4.16Effective January 1, 2013, Schedule 9 is hereby deleted.

5.All remaining terms and conditions of the Agreement remain in full force and effect.

The remainder of this page intentionally left blank

			
	

 IN WITNESS WHEREOF, and intending to be legally bound, the parties hereto have caused this Agreement to be duly executed in duplicate by their respective authorized representatives the day and year first written above.
									
	ORTHO-CLINICAL DIAGNOSTICS, INC		IDEXX OPERATIONS, INC.
	___________________________________		______________________________
			
	By:/s/ Eric Compton		By:/s/ Michael Williams
	Eric Compton		Michael Williams
	General Manager, WW Sales & Service		Vice President
			
	Date:  January 24, 2012		Date:  January 24, 2012
	___________________________________		______________________________
			

The foregoing Amendment is hereby consented to and acknowledged by:

IDEXX LABORATORIES, INC.,
solely as guarantor pursuant to Section 30 of the Agreement

IDEXX LABORATORIES, INC.

By:    /s/ Michael Williams 
Michael Williams Corporate Vice President

Date:  January 24, 2012

			
	

Schedule 5
Note: Price is for all slides up to the levels indicated below. New levels are triggered as the volume reaches the noted level. For clarity see example below.
Example Example Example
#1    #2    #3
Year of Purchase    [**]    [**]    [**]
Slide volume (a)    [**]    [**]    [**]
Price (b)    [**]    [**]    [**]
Total Purchase (a*b)    [**]    [**]    [**]
Slides (in MM)    2013    2014    2015    2016    2017    2018    2019    2020    2021    2022    2023    2024    2025    2026    2027    2028
                             [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]        [**]    [**]    [**]    [**]    [**]
                             [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]        [**]    [**]    [**]    [**]    [**]

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. A total of 15 pages were omitted pursuant to a request for confidential treatment.

[*] and [**] text omitted throughout this exhibit for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]